BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 12507965)

  • 1. Dual-label immunoassay for simultaneous measurement of prostate-specific antigen (PSA)-alpha1-antichymotrypsin complex together with free or total PSA.
    Zhu L; Leinonen J; Zhang WM; Finne P; Stenman UH
    Clin Chem; 2003 Jan; 49(1):97-103. PubMed ID: 12507965
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Determination of non-alpha1-antichymotrypsin-complexed prostate-specific antigen as an indirect measurement of free prostate-specific antigen: analytical performance and diagnostic accuracy.
    Wesseling S; Stephan C; Semjonow A; Lein M; Brux B; Sinha P; Loening SA; Jung K
    Clin Chem; 2003 Jun; 49(6 Pt 1):887-94. PubMed ID: 12765984
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Determination of alpha1-antichymotrypsin-PSA complex in serum does not improve the differentiation between benign prostatic hyperplasia and prostate cancer compared with total PSA and percent free PSA.
    Jung K; Brux B; Lein M; Knäbich A; Sinha P; Rudolph B; Schnorr D; Loening SA
    Urology; 1999 Jun; 53(6):1160-7; discussion 1167-8. PubMed ID: 10367846
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Generation of PSA-ACT-specific monoclonal antibodies and their application in a sandwich immunoassay.
    Wang TJ; Linton HJ; Payne J; Rittenhouse HG; Chan DW; Partin AW; Wolfert RL; Kuus-Reichel K
    Hybridoma; 1999 Dec; 18(6):535-41. PubMed ID: 10626683
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of the clinical validity of free prostate-specific antigen, alpha-1 antichymotrypsin-bound prostate-specific antigen and complexed prostate-specific antigen in prostate cancer diagnosis.
    Lein M; Jung K; Elgeti U; Petras T; Stephan C; Brux B; Sinha P; Winkelmann B; Schnorr D; Loening S
    Eur Urol; 2001 Jan; 39(1):57-64. PubMed ID: 11173940
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A multicenter clinical trial on the use of alpha1-antichymotrypsin-prostate-specific antigen in prostate cancer diagnosis.
    Lein M; Jung K; Hammerer P; Graefen M; Semjonow A; Stieber P; Ossendorf M; Luboldt HJ; Brux B; Stephan C; Schnorr D; Loening SA
    Prostate; 2001 May; 47(2):77-84. PubMed ID: 11340629
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ratio of alpha 1-antichymotrypsin--prostate specific antigen to total prostate specific antigen in prostate cancer diagnosis.
    Lein M; Jung K; Elgeti U; Brux B; Sinha P; Schnorr D; Loening SA
    Anticancer Res; 2000; 20(6D):4997-5001. PubMed ID: 11326657
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Advantages of replacing the total PSA assay with the assay for PSA-alpha 1-antichymotrypsin complex for the screening and management of prostate cancer.
    Wu JT; Liu GH
    J Clin Lab Anal; 1998; 12(1):32-40. PubMed ID: 9484667
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Percentage of free serum prostate-specific antigen: a new tool in the early diagnosis of prostatic cancer.
    Toubert ME; Guillet J; Chiron M; Meria P; Role C; Schlageter MH; Francois H; Borschneck C; Nivelon F; Desgrandchamps F; Rastel D; Cussenot O; Teillac P; Le Duc A; Najean Y
    Eur J Cancer; 1996 Nov; 32A(12):2088-93. PubMed ID: 9014750
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of the clinical performance of equimolar- and skewed-response total prostate-specific antigen assays versus complexed and free PSA assays and their ratios in discriminating between benign prostatic hyperplasia and prostate cancer.
    Wians FH; Cheli CD; Balko JA; Bruzek DJ; Chan DW; Sokoll LJ
    Clin Chim Acta; 2002 Dec; 326(1-2):81-95. PubMed ID: 12417099
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular forms of prostate-specific antigen in serum with concentrations of total prostate-specific antigen <4 microg/L: are they useful tools for early detection and screening of prostate cancer?
    Jung K; Stephan C; Elgeti U; Lein M; Brux B; Kristiansen G; Rudolph B; Hauptmann S; Schnorr D; Loening SA; Sinha P
    Int J Cancer; 2001 Sep; 93(5):759-65. PubMed ID: 11477592
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular forms of prostate-specific antigen in malignant and benign prostatic tissue: biochemical and diagnostic implications.
    Jung K; Brux B; Lein M; Rudolph B; Kristiansen G; Hauptmann S; Schnorr D; Loening SA; Sinha P
    Clin Chem; 2000 Jan; 46(1):47-54. PubMed ID: 10620571
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Determination of prostate-specific antigen complexed to alpha(2)-macroglobulin in serum increases the specificity of free to total PSA for prostate cancer.
    Zhang WM; Finne P; Leinonen J; Salo J; Stenman UH
    Urology; 2000 Aug; 56(2):267-72. PubMed ID: 10925092
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Proximity ligation measurement of the complex between prostate specific antigen and alpha1-protease inhibitor.
    Zhu L; Koistinen H; Landegren U; Stenman UH
    Clin Chem; 2009 Sep; 55(9):1665-71. PubMed ID: 19643837
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparisons of the various combinations of free, complexed, and total prostate-specific antigen for the detection of prostate cancer.
    Okegawa T; Noda H; Nutahara K; Higashihara E
    Eur Urol; 2000 Oct; 38(4):380-7. PubMed ID: 11025374
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ratio of free or complexed prostate-specific antigen (PSA) to total PSA: which ratio improves differentiation between benign prostatic hyperplasia and prostate cancer?
    Jung K; Elgeti U; Lein M; Brux B; Sinha P; Rudolph B; Hauptmann S; Schnorr D; Loening SA
    Clin Chem; 2000 Jan; 46(1):55-62. PubMed ID: 10620572
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discrimination of prostate cancer from benign disease by plasma measurement of intact, free prostate-specific antigen lacking an internal cleavage site at Lys145-Lys146.
    Nurmikko P; Pettersson K; Piironen T; Hugosson J; Lilja H
    Clin Chem; 2001 Aug; 47(8):1415-23. PubMed ID: 11468231
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Value of prostate specific antigen alpha1-antichymotrypsin complex for the detection of prostate cancer in patients with a PSA level of 4.1-10.0 ng/mL: comparison with PSA-related parameters.
    Miyake H; Hara S; Nomi M; Arakawa S; Kamidono S; Hara I
    Int J Urol; 2001 Nov; 8(11):589-93. PubMed ID: 11903683
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Free and complexed prostate-specific antigen (PSA): in vitro stability, epitope map, and development of immunofluorometric assays for specific and sensitive detection of free PSA and PSA-alpha 1-antichymotrypsin complex.
    Pettersson K; Piironen T; Seppälä M; Liukkonen L; Christensson A; Matikainen MT; Suonpää M; Lövgren T; Lilja H
    Clin Chem; 1995 Oct; 41(10):1480-8. PubMed ID: 7586521
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Electrophoretic subforms of free prostate-specific antigen in serum as promising diagnostic tool in prostate cancer diagnostics.
    Jung K; Hoesel W; Reiche J; Deger S; Kramer J; Loening SA; Lein M; Stephan C
    Urology; 2007 Feb; 69(2):320-5. PubMed ID: 17320672
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.